<DOC>
	<DOCNO>NCT01709747</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety hydromorphone hydrochloride administer intrathecal delivery .</brief_summary>
	<brief_title>Single-arm Study Assess Safety Hydromorphone Hydrochloride Intrathecal Administration</brief_title>
	<detailed_description>This open-label , single-arm safety study evaluate safety hydromorphone hydrochloride give continuous intrathecal infusion use implantable pump device . This study enroll subject current opioid intrathecal medication well na√Øve subject current intrathecal opioid medication . All subject currently intrathecal opioid treatment convert current intrathecal therapy intrathecal hydromorphone hydrochloride accord standard medical practice . After optimal dose pain relief achieve , subject remain therapy total 12 month discontinuation study . During continuous dose period , dose adjustment ( ) permit manage pain side effect provide maximum dose 10 mg/day exceed . Subjects assess pain intensity use visual analog scale pain intensity ( VASPI ) instrument study visit . Subjects evaluate side effect clinical complication associate use intrathecal hydromorphone . Events classify intrathecal drug use concentration .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Subjects must meet follow criterion include : 1 . Subjects must least 18 year age 75 year old . 2 . Clinically diagnose severe chronic pain least 6month period . 3 . Subject reasonably expect benefit intrathecal pain medication programmable implantable intrathecal pump meet clinical criterion implantation intrathecal pump per Standard Care . 4 . Subject agree sign Pain Treatment Agreement ( Narcotic Contract ) limit narcotic prescription study medication prescribe investigator . 5 . Subject must cognitively intact , opinion investigator , capable participation trial . 6 . Female subject childbearing potential must agree use medically acceptable effective doublebarrier method birth control . 7 . Subjects receive MRI require study protocol . 8 . Provides write Ethics Committee approve informed consent . 9 . Willing comply study procedures requirement . Subjects meet follow criterion exclude : 1 . Women pregnant breastfeeding . 2 . Subject know suspected allergy hydromorphone hydrochloride material infusion pump intrathecal catheter . 3 . Subject history dependence abuse opioids , stimulant , alcohol , benzodiazepine , define DSMIV criterion , within past year ( physical dependence prescribe opioid analgesic allow abuse opioids accord DSMIV permit , i.e . opioid addiction recreational use ) . 4 . Subjects show sign active systemic infection . 5 . Subjects metastatic cancer spinal canal know central nervous system contraindication intrathecal therapy . 6 . Subjects condition require diathermy procedure . 7 . Subject life expectancy le 12 month . 8 . Subjects unable unwilling return require followup visit . 9 . As result medical review physical examination , Investigator considers subject unfit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hydromorphone Hydrochloride</keyword>
	<keyword>Hydromorphone</keyword>
	<keyword>Pain</keyword>
	<keyword>Chronic Pain</keyword>
	<keyword>Implantable Pump</keyword>
	<keyword>Pump</keyword>
	<keyword>Intrathecal</keyword>
</DOC>